Business Description
Acumen Pharmaceuticals is a clinical-stage company working to develop new treatments for Alzheimer's disease. Its lead drug, Sabirnetug, is designed to target a specific form of amyloid-beta protein believed to drive the disease, and is currently being evaluated in a Phase 2 clinical trial following encouraging Phase 1 results. The company is also working with Halozyme to develop a version of the drug that patients could take by injection under the skin rather than through an IV. Founded in 1996 and based in Newton, Massachusetts, Acumen remains focused on bringing meaningful options to patients affected by Alzheimer's.
